Ribomic
Tokyo, Japan· Est.
Japanese biotech developing novel RNA aptamer therapeutics using proprietary RiboART platform technology, with focus on ophthalmology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese biotech developing novel RNA aptamer therapeutics using proprietary RiboART platform technology, with focus on ophthalmology.
Ophthalmology
Technology Platform
RiboART (Ribomic Aptamer Refined Therapeutics) system for discovering RNA aptamers that bind to target proteins with high affinity and specificity, based on SELEX technology.
Opportunities
Potential to develop first-in-class therapeutics across multiple disease areas using their versatile aptamer platform, with ophthalmology as an initial focus area.
Risk Factors
Clinical development risks for novel aptamer therapeutics, competition from established antibody drugs and other therapeutic modalities, and dependence on partnership revenue.
Competitive Landscape
Competes with other aptamer developers and traditional biologics companies; differentiates through proprietary RiboART platform and focus on generating first-in-class therapeutics with advantages over antibodies.